Healthcare Growth Partners
Healthcare Growth Partners is an investment banking and advisory firm focused exclusively on Health IT and Services. It publicly offers sell-side and buy-side M&A, capital advisory, and pre-transaction growth strategy services.
What stands out about Healthcare Growth Partners
Healthcare Growth Partners publicly positions itself as a selective Health IT and Services advisor offering sell-side and buy-side M&A, capital advisory, and pre-transaction growth strategy services. Its website reports 150+ transactions and $6 billion in aggregate transaction value.[1][3][4]
What does Healthcare Growth Partners do?
Healthcare Growth Partners is an investment banking and advisory firm exclusively focused on the transformational Health IT and Services market. It publicly describes a selective model serving select clients and focusing on a limited number of engagements.
The firm reports 150+ transactions and $6 billion in aggregate transaction value. Its office is listed at 2001 Kirby Drive, Suite 814, Houston, Texas 77019.[1][3][4]
Healthcare Growth Partners publicly offers Sell-Side M&A, Buy-Side M&A, Capital Advisory, and Pre-Transaction Growth Strategy services.[1]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Healthcare Growth Partners?
For an owner in Health IT or Services, Healthcare Growth Partners publicly describes a sector-exclusive advisory practice with sell-side M&A, capital advisory, and pre-transaction growth strategy services. Its stated selective-engagement model and transaction examples involving targeted and competitive processes provide specific points to discuss when evaluating an engagement.
An owner should clarify the proposed process, the senior professionals who would lead it, the intended buyer outreach strategy, the applicable legal entity, and the engagement economics. The transactions page does not disclose consideration or valuation for its listed examples, so comparable transaction detail and valuation methodology should be addressed directly.[1][2][3][5]
What retainer, success fee, expense, tail-period, and termination provisions would apply
What process options does HGP offer, and what factors determine whether it uses targeted outreach or a competitive auction
What size transactions and clients does Healthcare Growth Partners focus on?
Healthcare Growth Partners states that 100% of its transaction focus is Health IT and Services. Publicly identified transaction categories include payer technology and services, population health management, revenue cycle management, PM/EMR, infrastructure technology, and benefits management.[1][2]
Healthcare Growth Partners’ official archive identifies DUOS as having acquired Linkwell Health in 2026 and describes HGP’s role in sourcing, evaluating, and executing the acquisition. It also identifies Alora Health as having been acquired by LivTech in 2026, with HGP supporting preparation, buyer outreach, a dual-track process, and strategic guidance.
Other identified examples include Medisolv’s acquisition of Lilac Software in 2026; Tonic’s acquisition by Luma Health in 2025; eVideon’s acquisition by TigerConnect in 2025; and Envision Technology Partners’ acquisition by InductiveHealth in 2025. The archive describes HGP support across acquisition strategy, target outreach, targeted and competitive processes, diligence, negotiation, transaction structure, and board advice in these examples.[3]
The firm’s stated transaction services cover sell-side and buy-side M&A, capital advisory, and pre-transaction growth strategy. Its public transaction examples include acquisitions, competitive auctions, targeted processes, and buy-side acquisition support.[1][3]
What does Healthcare Growth Partners publicly disclose about fees, process and engagement terms?
The official transactions page identifies transaction names, years, sectors, transaction types, and process descriptions but does not disclose transaction consideration or valuation for the listed examples.
The official contact page provides a Houston office address and phone number but does not state a formal geographic coverage policy or service-territory definition.[3][4]
HGP Securities, LLC, CRD #148868 and SEC #8-68080, is identified in FINRA’s firm report as a brokerage firm regulated by FINRA’s Dallas Office. The report lists Healthcare Growth Partners, LLC as an alternate firm name.
Healthcare Growth Partners’ official website states that HGP Securities, LLC does business as Healthcare Growth Partners and is a member of FINRA and SIPC.[2][5]
Public transaction examples describe HGP involvement in sourcing and evaluating acquisitions, refining acquisition strategy, prioritizing targets, leading outreach, preparing sellers, conducting buyer outreach, coordinating diligence, negotiating terms, and advising on transaction structure.
The archive includes both targeted and competitive processes, including a targeted and competitive auction for Tonic and a competitive auction for Envision Technology Partners.[3]
Questions to ask before hiring Healthcare Growth Partners
Which legal entity would sign the engagement letter and receive fees?
What retainer, success fee, expense, tail-period, and termination provisions would apply?
What process options does HGP offer, and what factors determine whether it uses targeted outreach or a competitive auction?
Which recent comparable transactions can HGP discuss privately, including valuation ranges and buyer feedback?
What geographic coverage would apply to the proposed engagement?
Which senior professionals would lead the engagement, and how would their role align with HGP's selective-engagement model?
Sources & research notes
- Official website / firm overview
- Industry / market focus
- Transaction size / criteria
- Geography / market coverage
- FINRA regulatory record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.